In fact, the reduction of inflammatory cytokines, particularly IL-1β, following inflammasome inhibition may suggest a potential modulation of TAM activity as confirmed in activated THP-1 macrophages, supporting the notion that inflammasome inhibition acts on non-tumor cells to enhance sorafenib efficacy. The gene discussed is IL1B; the disease is neoplasm.